3-(2-bromo-4-chlorophenyl)propanoic acid | 66192-04-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-(2-bromo-4-chlorophenyl)propanoic acid
• 英文别名: 3-(2-Bromo-4-chlorophenyl)propanoic acid
• CAS: 66192-04-9
• 化学式: C₉H₈BrClO₂
• 分子量: 263.518
• InChiKey: XHXKZBOVNCLNHW-UHFFFAOYSA-N

物化性质

• 沸点：
  357.9±27.0 °C(Predicted)
• 密度：
  1.631±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(2-bromo-4-chlorophenyl)propanoic acid 在 盐酸 、 aluminum (III) chloride 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium fluoride 、 氯化亚砜 、 tetraphosphorus decasulfide 、 水 、 四氯化钛 作用下， 以 甲醇 、 二氯甲烷 、 二甲基亚砜 为溶剂， 生成 2-[(6-chloro-1,1-dimethyl-2,3-dihydroinden-4-yl)methyl]-4,5-dihydro-1H-imidazole;hydrochloride
  参考文献：
  名称：

  Discovery of potent α1L-adrenoceptor agonists: Design and synthesis of bicyclic derivatives

  摘要：

  We aimed to create a novel and potent alpha(1L)-adrenoceptor agonist because such agonists are possible drug candidates for stress urinary incontinence. We used ligand-based drug design and evaluated the alpha(1L)-adrenoceptor agonist activity of the designed compounds. Among them, tetrahydroquinoline derivative 50 showed the most potent activity (ratio of noradrenaline half maximal effective concentration, 0.0028) and effectively induced contraction of rat bladder neck. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.05.049
• 作为产物：
  描述：

  3-(4-氯苯基)丙酸 在 gold(III) chloride 、 N-溴代丁二酰亚胺(NBS) 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 3-(2-bromo-4-chlorophenyl)propanoic acid
  参考文献：
  名称：

  Discovery of potent α1L-adrenoceptor agonists: Design and synthesis of bicyclic derivatives

  摘要：

  We aimed to create a novel and potent alpha(1L)-adrenoceptor agonist because such agonists are possible drug candidates for stress urinary incontinence. We used ligand-based drug design and evaluated the alpha(1L)-adrenoceptor agonist activity of the designed compounds. Among them, tetrahydroquinoline derivative 50 showed the most potent activity (ratio of noradrenaline half maximal effective concentration, 0.0028) and effectively induced contraction of rat bladder neck. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.05.049

文献信息

• [EN] SUBSTITUTED OXOPYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS D'OXOPYRIDINE SUBSTITUÉS
  申请人：BAYER AG

  公开号：WO2020127504A1

  公开（公告）日：2020-06-25

  The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular vascular disorders, preferably thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications.

  这项发明涉及替代氧吡啶衍生物及其制备方法，以及它们用于制备药物治疗和/或预防疾病，特别是血管疾病，最好是血栓性或血栓栓塞性疾病和/或血栓性或血栓栓塞性并发症。
• [EN] NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS<br/>[FR] NOUVEAUX DÉRIVÉS D'ACIDE INDANYLOXYDIHYDROBENZOFURANNYLACÉTIQUE ET LEUR UTILISATION COMME AGONISTES DU RÉCEPTEUR GPR40
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2013144098A1

  公开（公告）日：2013-10-03

  The present invention relates to compounds of general formula (I), wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及一般式(I)的化合物，其中基团R1、R2和m的定义如权利要求书中所述，这些化合物具有有价值的药理特性，特别是与GPR40受体结合并调节其活性。这些化合物适用于治疗和预防受该受体影响的疾病，如代谢性疾病，特别是2型糖尿病。
• NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2831053A1

  公开（公告）日：2015-02-04
• SUBSTITUTED OXOPYRIDINE DERIVATIVES
  申请人：Bayer Aktiengesellschaft

  公开号：EP3898633A1

  公开（公告）日：2021-10-27